Voyager2: Safety, Tolerability, PK & PD of oral Inno8 in People with Hemophilia A

Inclusion Criteria:
*  Male
*  Age 18-64 years (both inclusive) at the time of signing the informed consent.
*  Body weight greater than or equal to (≥) 45 kilograms (kgs).
*  Diagnosis of congenital haemophilia A with factor VIII (FVIII) activity less than or equal to (≤) 15 percentage (%) with or without FVIII inhibitors, based on medical records.

Exclusion Criteria:
*  Current or prior exposure to any prophylactic treatment for haemophilia A within 5 half-lives of the medicinal product by the time of screening.
*  Body mass index ≥30.0 kilogram per square meter (kg/m\^2).
*  Increased risk of thrombosis, e.g. known history of personal or first-degree relative(s) with unprovoked deep vein thrombosis.
*  Any clinical signs or established diagnosis of venous or arterial thromboembolic disease.
*  Any known coagulation disorders other than haemophilia A.
*  Ongoing or planned immune tolerance induction therapy.
*  Presence of clinically significant gastrointestinal disorders potentially affecting absorption of drugs and/or nutrients, as judged by the investigator.